Elevate your enterprise data technology and strategy at Transform 2021.


Nora Pharmaceuticals, developer of women’s reproductive health drugs and devices, brought in $25 million in first round financing from Burrill & Co., Prospect Venture Partners and Vivo Ventures. The San Francisco-based company is still pretty stealthy (it doesn’t even have a website). It did release that it has some products, but did not specify further.

There is a lot of investor interest in this area of healthcare right now, reports VentureWire. Swiss startup Lumavita, for example, just received $15.4 million to develop treatments for conditions caused by HPV in women. Agile Therapeutics brought in $17.6 million last year to continue work on a once-weekly contraceptive patch. And Interlace Medical raised $7 million for gynecological instruments.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member